310 related articles for article (PubMed ID: 12733223)
1. Drugs and vaccines for the common defense: refining FDA regulation to promote the availability of products to counter biological attacks.
Javitt GH
J Contemp Health Law Policy; 2002; 19(1):37-116. PubMed ID: 12733223
[No Abstract] [Full Text] [Related]
2. Combination products regulation at the FDA.
Lauritsen KJ; Nguyen T
Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
[TBL] [Abstract][Full Text] [Related]
3. Old legacies and new paradigms: confusing "research" and "treatment" and its consequences in responding to emergent health threats.
Javitt GH
J Health Care Law Policy; 2005; 8(1):38-70. PubMed ID: 16538801
[No Abstract] [Full Text] [Related]
4. Perspectives. Approval process a moving target in FDA reform hearings.
Rhein R
Faulkner Grays Med Health; 1996 Feb; 50(8):suppl 1-4. PubMed ID: 10154482
[No Abstract] [Full Text] [Related]
5. FDA not NIH can speed new drugs.
Miller HI
Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657
[No Abstract] [Full Text] [Related]
6. Today's FDA.
Slater EE
N Engl J Med; 2005 Jan; 352(3):293-7. PubMed ID: 15659733
[No Abstract] [Full Text] [Related]
7. Biogenerics standoff.
Herrera S
Nat Biotechnol; 2004 Nov; 22(11):1343-6. PubMed ID: 15529145
[No Abstract] [Full Text] [Related]
8. Communicating with the FDA: the "third rail" of a new model for drug development.
Stanski DR; Orloff JJ
J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
[No Abstract] [Full Text] [Related]
9. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
Kesselheim AS
Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908
[No Abstract] [Full Text] [Related]
10. Who would approve new drugs if there were no FDA?
Gatty B
Hosp Formul; 1995 Jan; 30(1):58, 57. PubMed ID: 10139726
[No Abstract] [Full Text] [Related]
11. The history and contemporary challenges of the US Food and Drug Administration.
Borchers AT; Hagie F; Keen CL; Gershwin ME
Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
[TBL] [Abstract][Full Text] [Related]
12. The FDA is no place for politics.
Nat Struct Mol Biol; 2006 May; 13(5):379. PubMed ID: 16738601
[No Abstract] [Full Text] [Related]
13. Biodefense: who's in charge?
Sutton V
Health Matrix Clevel; 2003; 13(1):117-58. PubMed ID: 14569660
[No Abstract] [Full Text] [Related]
14. Blinded by bioterrorism: public health and liberty in the 21st century.
Annas GJ
Health Matrix Clevel; 2003; 13(1):33-70. PubMed ID: 14569657
[No Abstract] [Full Text] [Related]
15. Muddied messages about FDA.
Miller HI
Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
[No Abstract] [Full Text] [Related]
16. US FDA review and regulation of preventive vaccines for infectious disease indications: impact of the FDA Amendments Act 2007.
Gruber MF
Expert Rev Vaccines; 2011 Jul; 10(7):1011-9. PubMed ID: 21806396
[TBL] [Abstract][Full Text] [Related]
17. What ails the FDA?
Jenny-Avital ER
N Engl J Med; 2005 Jun; 352(24):2554-5. PubMed ID: 15962407
[No Abstract] [Full Text] [Related]
18. Should you let the FDA decide what drugs you pay for?
Dutton G
Bus Health; 1996 Oct; 14(10):65, 69-70, 73. PubMed ID: 10161492
[No Abstract] [Full Text] [Related]
19. Regulating biopharmaceuticals under CDER versus CBER: an insider's perspective.
Schwieterman WD
Drug Discov Today; 2006 Oct; 11(19-20):945-51. PubMed ID: 16997146
[TBL] [Abstract][Full Text] [Related]
20. Looking for solid ground along the Critical Path.
Ratner M
Nat Biotechnol; 2006 Aug; 24(8):885-7. PubMed ID: 16900118
[No Abstract] [Full Text] [Related]
[Next] [New Search]
